/
Other
Colitis, Ulcerative
18
Pipeline Programs↗
21
Active Trials↗
9
Companies Involved↗
Colitis, Ulcerative is an emerging landscape with 18 programs across 9 companies. The most active players are Johnson & Johnson, Eli Lilly, Pfizer. 10 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Phase 24
Phase 310
Approved
No programs
Analysis
Modality Breakdown
10programs
Small molecule550%
Monoclonal antibody550%
Modality classified for 61% of 18 pipeline programs.
Analysis
Trial Status
22
clinical trials
Recruiting9 · 41%
Active, not recruiting9 · 41%
Not yet recruiting3 · 14%
Completed1 · 5%
Clinical Trials
Trial Activity
22 trials
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)